Compounds > dpc 961
Page last updated: 2024-11-08

dpc 961

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID474120
CHEMBL ID283619
SCHEMBL ID1045118
MeSH IDM0370096

Synonyms (24)

Synonym
chembl283619 ,
bdbm2898
(4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-2-one
dpc961
214287-88-4
(4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
2(1h)-quinazolinone, 6-chloro-4-(cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-, (4s)-
dpc 961
dmp-961
dpc-961
(4s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-1h-quinazolin-2-one
unii-i9u2grq1uf
i9u2grq1uf ,
2(1h)-quinazolinone, 6-chloro-4-(2-cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-, (4s)-
(-)-dmp-961
(s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-2(1h)-quinazolinone
(s)-dpc-961
SCHEMBL1045118
DTXSID30175699
AKOS030241781
(4s)-6-chloro-4-(2-cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-2(1h)-quinazolinone
Q27280617
(s)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1h)-one
jjwjsiajlbemen-zdusscgksa-n

Research Excerpts

Overview

DPC 961 is a low-solubility, high-permeability, second-generation non-nucleoside reverse transcriptase inhibitor.

ExcerptReferenceRelevance
"DPC 961 is a low-solubility, high-permeability, second-generation non-nucleoside reverse transcriptase inhibitor. "( Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent.
Aungst, BJ; Bindra, DS; Nguyen, NH; Taylor, NJ, 2002)		1.76

Bioavailability

ExcerptReferenceRelevance
" The best compounds are potent orally bioavailable inhibitors of both wild-type HIV-1 and its clinically relevant K103N mutant virus, but are highly protein-bound in human plasma."( 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
Bacheler, LT; Chidester, DR; Cocuzza, AJ; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Jeffrey, S; Klabe, RM; Ko, SS; Rodgers, JD; Weigelt, CA, 2001)		0.31
" Bioavailability with an unoptimized tablet formulation was 30% in fasted dogs and 86% in fed dogs."( Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent.
Aungst, BJ; Bindra, DS; Nguyen, NH; Taylor, NJ, 2002)		0.31

Dosage Studied

The stability of the DPC 961 and 963 in the dosing formulation was followed over a 24-h period using a stability indicating HPLC method. To accomplish this, groups of four to six dogs were dosed with various formulations of D PC 961 under fasted or fed conditions. The pharmacokinetics were examined.

ExcerptRelevanceReference
" The stability of the DPC 961 and 963 in the dosing formulation was followed over a 24-h period using a stability indicating HPLC method."( In-use testing of extemporaneously prepared suspensions of second generation non-nucleoside reversed transcriptase inhibitors in support of phase I clinical studies.
Aubry, AF; Gray, V; Hobson, T; Rabel, S; Sebastian, D; Xie, M; Xu, JQ, 2000)		0.62
" To accomplish this, groups of four to six dogs were dosed with various formulations of DPC 961 under fasted or fed conditions, and DPC 961 pharmacokinetics were examined."( Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent.
Aungst, BJ; Bindra, DS; Nguyen, NH; Taylor, NJ, 2002)		0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.03200.00060.91418.3200AID1795434
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.04740.00011.076810.0000AID1272056; AID197777; AID197782; AID198399; AID198563
Protease Human immunodeficiency virus 1IC50 (µMol)0.03100.00010.22487.3200AID143392
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC90 (µMol)0.01870.00170.03850.3100AID1272056; AID143399; AID198574; AID198578; AID81765; AID81766; AID94447
Protease Human immunodeficiency virus 1IC90 (µMol)0.45000.00200.67847.3000AID143394; AID143396; AID143398; AID143402; AID94449
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1795434HIV-1 RT Assay from Article 10.1016/s0960-894x(01)00239-6: \\4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.\\2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID152945Antiviral activity against A018C, Zidovudine resistant clinical strain of HIV in PBMC by P24 assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94447Inhibitory concentration against wild-type virus K103N and HIV-1 RT mutant in a whole cell antiviral assay2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID96290In vitro antiviral activity against HIV-1 (L100I).2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID222922percentage of the free compound in human serum2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID222294Effect of human plasma protein binding on antiviral efficacy.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1272056Inhibition of HIV1 reverse transcriptase2016European journal of medicinal chemistry, Jan-27, Volume: 108Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
AID141355Calculated Potency against Mutant HIV-1 sV179D/L100I/Y181C2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID166685Compound was evaluated for the inhibition of wide-type RF strain of HIV-12000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID143398Compound was evaluated for its ability to inhibit the mutant K103N NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID106728Antiviral activity against RF strain of HIV in MT-2 cells by yield assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID227244The compound was evaluated for antiviral activity using whole cell assay2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
AID222923percentage of the free compound in tissue culture medium2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID141356Plasma Potency against Mutant HIV-1 sV179D/L100I/Y181C2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID198578Inhibitory concentration against HIV-1 reverse transcriptase2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID198399Tested for inhibitory concentration against HIV-1 non-nucleoside reverse transcriptase2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID81766Compound was evaluated for its ability to inhibit the wild type RF strain of HIV-12001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID96292Potency against Mutant HIV-1 sL100I2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94312Calculated Potency against Mutant HIV-1 K103N2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94313Antiviral activity toward K103N mutant HIV-1 virus as protein binding adjusted (PB adj).2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID143402Compound was evaluated for its ability to inhibit the mutant K103N V1081NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID94314Antiviral activity against HIV-1 K103N mutant virus.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID166687Plasma antiviral activity was evaluated for RF strain of HIV-12000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106730Antiviral activity against E, Zidovudine resistant clinical strain of HIV in MT-2 cells by yield assay; ND is Not Determined.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID141357Potency against Mutant HIV-1 sV179D/L100I/Y181C2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94440Plasma Potency against Mutant HIV-1 K103N2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID96291Plasma Potency against Mutant HIV-1 sL100I2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106726Antiviral activity against HIV-2 in MT-2 cells by yield assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID94442Potency against Mutant HIV-1 K103N2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID152946Antiviral activity against Thai 9466, a wild-type clinical strain of HIV in PBMC by P24 assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106729Protein Binding was evaluated by PB shift in MT-2 by RNA assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID229259Antiviral activity was evaluated for the inhibition of wild-type RF strain of HIV-1 in an in vitro enzyme assay.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID198574Compound was evaluated for the inhibition of HIV-1 Reverse transcriptase2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID106727Antiviral activity against RF strain of HIV in MT-2 cells by RNA assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID143392Compound was evaluated for its ability to inhibit the NNRTI HIV-1 enzyme by 50% using enzyme assay2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID143399Compound was evaluated for its ability to inhibit the mutant K103N P225H NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID197782Inhibition of HIV-1 reverse transcriptase.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID96289Calculated Potency against Mutant HIV-1 sL100I2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID81765Compound was evaluated for its ability to inhibit a virus containing the clinically relevant K103N mutation2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID197777Compound was evaluated for its ability to inhibit HIV-1 Reverse Transcriptase in an in vitro enzyme assay2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
AID198563The compound was evaluated for the inhibition of HIV-1 reverse transcriptase2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
AID94449Inhibitory concentration against wild-type virus K103N/L1001 and HIV-1 RT double mutant in whole cell antiviral assay2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
AID143394Compound was evaluated for its ability to inhibit the NNRTI HIV-1 enzyme by 90% using whole cell assay2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID143396Compound was evaluated for its ability to inhibit the mutant K103N L1001 NNRTI HIV-1 enzyme2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
AID493017Wombat Data for BeliefDocking2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (86.67)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.69 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nsc 615985
NSC 615985: structure given in first source; potent inhibitor of HIV reproduction		2.0210
ag-1549
capravirine: a non-nucleoside reverse transcriptase inhibitor		2.0210
aurintricarboxylic acid
Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues.. aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'.		2.0210monohydroxybenzoic acid;
quinomethanes;
tricarboxylic acid		fluorochrome;
histological dye;
insulin-like growth factor receptor 1 antagonist
loviride
loviride: structure given in first source; inhibits virion and recombinant HIV-1 reverse transcriptase		2.0210
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.730cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		2.4220aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		210monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		3.5180azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		4.6280acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		2.0210aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
l-697661
L-697661: HIV-1 reverse transcriptase inhibitor		210
emivirine
emivirine: a non-nucleoside inhibitor of HIV-1 reverse transcriptase. emivirine : A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV.		2.0210pyrimidoneantiviral drug;
HIV-1 reverse transcriptase inhibitor
rosiglitazone
[no description available]		2.0610aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid: used as a substitute for amino acids in synthetic peptides		2.0610
gw420867x
GW420867X: structure in first source		3.2310
oxirene
oxirene: structure		710mancude organic heteromonocyclic parent;
monocyclic heteroarene;
oxacycle
delavirdine mesylate
delavirdine mesylate : The monomethanesulfonic acid salt of delavirdine, a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		210methanesulfonate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor
tnk-651
TNK-651: Reverse Transcriptase Inhibitor; structure in first source. 6-benzyl-1-(benzyloxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by benzyloxymethyl, isopropyl, and benzyl groups, respectively.		2.0210pyrimidone
dpc 963
DPC 963: structure in first source		2.4120
r 86183
[no description available]		2.0210
nsc 629243
NSC 629243: structure given in first source; an anti-HIV drug		2.0210
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.0210
uc-781
[no description available]		2.0210
ly 73497
LY 73497: HIV-1 reverse transcriptase inhibitor; structure in first source		2.0210
dpc 083
[no description available]		4.2150
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.0110
HIV Coinfection
[description not available]		0210
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		0210